Reach Us +44-1904-929220
Secretome Analysis Of Large Cell Lung Cancer Cell Lines Using Two-dimensional Electrophoresis Coupled To Mass Spectrometry | 3653

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Secretome analysis of large cell lung cancer cell lines using two-dimensional electrophoresis coupled to mass spectrometry

2nd World Congress on Biomarkers & Clinical Research

Zahra Mojtahedi

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

The secretome of cancer cells is a valuable source of biomarkers that can ultimately reach the serum or other body fl uids. Cancer biomarkers can facilitate early disease detection and monitoring, contribute to our understanding of the biology of cancer, and support the development of more effi cient therapies. Recently, high-throughput proteomic analysis of the conditioned media of cancer cell lines has shown potential to identify novel biomarkers in cancer. We used two-dimensional electrophoresis coupled to liquid chromatography tandem mass spectrometry to identify the proteomes of the large cell lung cancer cell lines QU-DB and Mehr-80. A total of 130 distinct protein species were identifi ed. Of these, 79 were previously found in serum or other body fl uids, the membrane compartment or conditioned media of other cancer cell lines. Some of the proteins that we identifi ed, e.g. IL-6, ubiquitincarboxyl- terminal hydrolase isozyme L1 (PGP9.5), α-enolase, peroxiredoxin-1 are known putative serum markers for lung cancer, whereas others might be candidate markers for further validation in lung cancer body fl uids such as epidermal fatty acid-binding protein, peptidyl-prolyl cis-trans isomerase A, chloride intracellular channel protein 1 and 4
Zahra Mojtahedi has completed her medical doctor in 1998 and Ph.D in 2008 from Shiraz University of Medical Sciences. She has published more than 20 articles, and she is the director of Proteomics Lab in Shiraz Institute for Cancer Research, in Shiraz, Iran.
Relevant Topics